
|Articles|December 4, 2009
FDA approves therapy for advanced renal cell carcinoma
Author(s)Urology Times staff
The FDA has approved GlaxoSmithKline's pazopanib (Votrient) to treat patients with advanced renal cell carcinoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5











